Comparison of PolarityTE Inc. (PTE) and Amicus Therapeutics Inc. (NASDAQ:FOLD)

Both PolarityTE Inc. (NASDAQ:PTE) and Amicus Therapeutics Inc. (NASDAQ:FOLD) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PolarityTE Inc. 1.56M 222.41 74.16M -5.22 0.00
Amicus Therapeutics Inc. 73.33M 33.34 340.12M -1.89 0.00

In table 1 we can see PolarityTE Inc. and Amicus Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
PolarityTE Inc. -4,753.85% 0% 0%
Amicus Therapeutics Inc. -463.82% -73.6% -43%

Volatility & Risk

A beta of 1.19 shows that PolarityTE Inc. is 19.00% more volatile than Standard and Poor’s 500. Amicus Therapeutics Inc.’s 1.49 beta is the reason why it is 49.00% more volatile than Standard and Poor’s 500.


The Current Ratio of PolarityTE Inc. is 18.5 while its Quick Ratio stands at 18.4. The Current Ratio of rival Amicus Therapeutics Inc. is 9.1 and its Quick Ratio is has 9. PolarityTE Inc. is better equipped to clear short and long-term obligations than Amicus Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for PolarityTE Inc. and Amicus Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PolarityTE Inc. 0 0 0 0.00
Amicus Therapeutics Inc. 0 1 3 2.75

Competitively the average price target of Amicus Therapeutics Inc. is $16.25, which is potential 44.83% upside.

Institutional & Insider Ownership

PolarityTE Inc. and Amicus Therapeutics Inc. has shares held by institutional investors as follows: 54.2% and 0%. PolarityTE Inc.’s share held by insiders are 35%. Comparatively, 0.2% are Amicus Therapeutics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PolarityTE Inc. -4.26% 1% -26.16% -49.19% -51.72% -38.95%
Amicus Therapeutics Inc. -3.89% -7.01% -11.58% -30.83% -17.72% -26.27%

For the past year PolarityTE Inc.’s stock price has bigger decline than Amicus Therapeutics Inc.


Amicus Therapeutics Inc. beats PolarityTE Inc. on 6 of the 11 factors.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.